On April 22, 2020, the Third Circuit Court of Appeals vacated and remanded an order certifying a class of direct purchaser plaintiffs in In re: Lamictal Direct Purchaser Antitrust Litigation, holding that the district court...more
4/30/2020
/ Antitrust Injuries ,
Antitrust Litigation ,
Appeals ,
Burden of Proof ,
Class Certification ,
Delays ,
Direct Purchasers ,
FRCP 23 ,
FRCP 23(b)(3) ,
Generic Drugs ,
Manufacturers ,
Pharmaceutical Industry ,
Predominance Requirement ,
Remand ,
Reverse Payment Settlement Agreements ,
Vacated ,
Wholesale
The U.S. Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, Inc. triggered a flurry of judicial activity in relation to pharmaceutical patent settlements allegedly involving reverse payments from patent...more